Testing SHetA2 for advanced solid tumor cancers
Part of Cancer clinical trials.
This early-phase study tests SHetA2, a new treatment, in people whose solid tumor cancer has returned or grown despite other treatments. It’s designed to check safety and see whether the treatment can help shrink or control cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor cancer that has come back or progressed after available treatments, and you can provide the original pathology (biopsy) report.
- You must have enough body function for treatment, including bone marrow, kidney, and liver levels that meet the study lab cutoffs.
- Your blood clotting test results (INR/PT and aPTT) must be near normal (or be in the correct range if you take blood thinners).
- Your nerve symptoms must be mild (neuropathy at most mild/moderate—Grade 1), and you must not have a serious uncontrolled illness or an active infection needing IV antibiotics within 4 weeks.
- You must be able to take pills by mouth and have life expectancy of at least 3 months; you also must be at least 18 years old and able to follow study visits and tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-A2102, alone or with other cancer treatments, for people with advanced solid tumors that haven't responded well to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called SHR-3821 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.
This trial is testing an investigational drug called SHR-7787 for people with advanced solid tumors (cancer that has spread or can't be removed). The goal is to see if it is safe and how well it works. It may be an option if your tumor type is no longer responding to other treatments.
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.